Annual Cash & Cash Equivalents
$5.84 B
-$326.00 M-5.29%
31 December 2023
Summary:
AstraZeneca annual cash & cash equivalents is currently $5.84 billion, with the most recent change of -$326.00 million (-5.29%) on 31 December 2023. During the last 3 years, it has fallen by -$1.99 billion (-25.43%). AZN annual cash & cash equivalents is now -45.41% below its all-time high of $10.70 billion, reached on 31 December 2010.AZN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$4.80 B
-$2.12 B-30.64%
30 September 2024
Summary:
AstraZeneca quarterly cash and cash equivalents is currently $4.80 billion, with the most recent change of -$2.12 billion (-30.64%) on 30 September 2024. Over the past year, it has dropped by -$74.00 million (-1.52%). AZN quarterly cash and cash equivalents is now -69.18% below its all-time high of $15.57 billion, reached on 30 June 2021.AZN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -5.3% | -1.5% |
| 3 y3 years | -25.4% | -32.1% |
| 5 y5 years | +23.1% | +20.9% |
AZN Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -25.4% | at low | -38.8% | +7.6% |
| 5 y | 5 years | -25.4% | +23.1% | -69.2% | +40.5% |
| alltime | all time | -45.4% | +4418.8% | -69.2% |
AstraZeneca Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.80 B(-30.6%) |
| June 2024 | - | $6.92 B(-11.8%) |
| Mar 2024 | - | $7.84 B(+34.3%) |
| Dec 2023 | $5.84 B(-5.3%) | $5.84 B(+19.9%) |
| Sept 2023 | - | $4.87 B(-14.0%) |
| June 2023 | - | $5.66 B(-9.1%) |
| Mar 2023 | - | $6.23 B(+1.1%) |
| Dec 2022 | $6.17 B(-2.6%) | $6.17 B(+38.3%) |
| Sept 2022 | - | $4.46 B(-7.5%) |
| June 2022 | - | $4.82 B(-16.4%) |
| Mar 2022 | - | $5.76 B(-9.0%) |
| Dec 2021 | $6.33 B(-19.2%) | $6.33 B(-10.4%) |
| Sept 2021 | - | $7.07 B(-54.6%) |
| June 2021 | - | $15.57 B(+103.9%) |
| Mar 2021 | - | $7.64 B(-2.5%) |
| Dec 2020 | $7.83 B(+45.9%) | $7.83 B(-3.0%) |
| Sept 2020 | - | $8.07 B(+42.3%) |
| June 2020 | - | $5.67 B(+66.2%) |
| Mar 2020 | - | $3.41 B(-36.4%) |
| Dec 2019 | $5.37 B(+13.1%) | $5.37 B(+35.3%) |
| Sept 2019 | - | $3.97 B(-26.9%) |
| June 2019 | - | $5.43 B(+31.2%) |
| Mar 2019 | - | $4.14 B(-12.8%) |
| Dec 2018 | $4.75 B(+42.7%) | $4.75 B(+38.7%) |
| Sept 2018 | - | $3.42 B(+14.8%) |
| June 2018 | - | $2.98 B(-0.9%) |
| Mar 2018 | - | $3.00 B(-9.6%) |
| Dec 2017 | $3.32 B(-32.5%) | $3.32 B(-17.6%) |
| Sept 2017 | - | $4.04 B(-23.0%) |
| June 2017 | - | $5.24 B(+67.4%) |
| Mar 2017 | - | $3.13 B(-36.5%) |
| Dec 2016 | $4.93 B(-19.6%) | $4.93 B(+59.4%) |
| Sept 2016 | - | $3.09 B(-21.1%) |
| June 2016 | - | $3.92 B(+14.2%) |
| Mar 2016 | - | $3.43 B(-44.1%) |
| Dec 2015 | $6.13 B(-1.9%) | $6.13 B(+50.2%) |
| Sept 2015 | - | $4.08 B(+2.9%) |
| June 2015 | - | $3.97 B(+24.3%) |
| Mar 2015 | - | $3.19 B(-48.9%) |
| Dec 2014 | $6.25 B(-31.3%) | $6.25 B(+21.4%) |
| Sept 2014 | - | $5.15 B(+3.8%) |
| June 2014 | - | $4.96 B(+13.2%) |
| Mar 2014 | - | $4.38 B(-51.9%) |
| Dec 2013 | $9.10 B(+22.9%) | $9.10 B(+22.1%) |
| Sept 2013 | - | $7.45 B(-9.7%) |
| June 2013 | - | $8.25 B(+14.1%) |
| Mar 2013 | - | $7.23 B(-2.2%) |
| Dec 2012 | $7.40 B(+5.3%) | $7.40 B(+23.0%) |
| Sept 2012 | - | $6.02 B(-21.3%) |
| June 2012 | - | $7.64 B(+20.7%) |
| Mar 2012 | - | $6.33 B(-9.9%) |
| Dec 2011 | $7.03 B(-34.3%) | $7.03 B(-28.7%) |
| Sept 2011 | - | $9.86 B(+2.6%) |
| June 2011 | - | $9.61 B(+0.3%) |
| Mar 2011 | - | $9.58 B(-10.4%) |
| Dec 2010 | $10.70 B | $10.70 B(+6.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2010 | - | $10.01 B(+10.1%) |
| June 2010 | - | $9.09 B(+23.4%) |
| Mar 2010 | - | $7.37 B(-25.7%) |
| Dec 2009 | $9.92 B(+131.4%) | $9.92 B(+27.3%) |
| Sept 2009 | - | $7.79 B(+8.3%) |
| June 2009 | - | $7.20 B(+62.0%) |
| Mar 2009 | - | $4.44 B(+3.6%) |
| Dec 2008 | $4.29 B(-26.9%) | $4.29 B(+21.0%) |
| Sept 2008 | - | $3.54 B(-18.4%) |
| June 2008 | - | $4.34 B(+48.6%) |
| Mar 2008 | - | $2.92 B(-50.2%) |
| Dec 2007 | $5.87 B(-17.4%) | $5.87 B(+71.1%) |
| Sept 2007 | - | $3.43 B(-30.8%) |
| June 2007 | - | $4.95 B(-11.1%) |
| Mar 2007 | - | $5.57 B(-21.6%) |
| Dec 2006 | $7.10 B(+42.7%) | $7.10 B(+23.4%) |
| Sept 2006 | - | $5.76 B(-5.3%) |
| June 2006 | - | $6.08 B(-14.5%) |
| Mar 2006 | - | $7.10 B(+42.7%) |
| Dec 2005 | $4.98 B(+371.9%) | $4.98 B(+13.2%) |
| Sept 2005 | - | $4.40 B(-19.3%) |
| June 2005 | - | $5.45 B(+9.5%) |
| Mar 2005 | - | $4.98 B(+371.9%) |
| Dec 2004 | $1.05 B(+43.9%) | $1.05 B(+3.4%) |
| Sept 2004 | - | $1.02 B(-32.0%) |
| June 2004 | - | $1.50 B(+84.2%) |
| Mar 2004 | - | $814.00 M(+11.1%) |
| Dec 2003 | $733.00 M(+1.0%) | $733.00 M(>+9900.0%) |
| Sept 2003 | - | $0.00(-100.0%) |
| June 2003 | - | $4.00 B(>+9900.0%) |
| Mar 2003 | - | $0.00(-100.0%) |
| Dec 2002 | $726.00 M(+3.0%) | $726.00 M(>+9900.0%) |
| Sept 2002 | - | $0.00(-100.0%) |
| June 2002 | - | $4.27 B(>+9900.0%) |
| Mar 2002 | - | $0.00(-100.0%) |
| Dec 2001 | $705.00 M(-31.0%) | $705.00 M(>+9900.0%) |
| Sept 2001 | - | $0.00(-100.0%) |
| June 2001 | - | $4.26 B(>+9900.0%) |
| Mar 2001 | - | $0.00(-100.0%) |
| Dec 2000 | $1.02 B(+138.1%) | $1.02 B(>+9900.0%) |
| Sept 2000 | - | $0.00(-100.0%) |
| June 2000 | - | $2.95 B(>+9900.0%) |
| Mar 2000 | - | $0.00(-100.0%) |
| Dec 1999 | $429.00 M(-86.3%) | $429.00 M(-88.7%) |
| Sept 1999 | - | $3.79 B(+88.1%) |
| June 1999 | - | $2.02 B(-35.8%) |
| Dec 1998 | $3.14 B(+526.5%) | $3.14 B(+859.6%) |
| June 1998 | - | $327.00 M(-34.7%) |
| Dec 1997 | $500.89 M(+12.9%) | $500.89 M(+12.9%) |
| Dec 1996 | $443.54 M(+76.1%) | $443.54 M(+76.1%) |
| Dec 1995 | $251.87 M(-70.6%) | $251.87 M(-73.8%) |
| June 1995 | - | $961.50 M(+12.2%) |
| Dec 1994 | $856.75 M(-36.6%) | $856.75 M(-36.6%) |
| Dec 1993 | $1.35 B(+190.4%) | $1.35 B |
| Dec 1992 | $465.62 M(-1.6%) | - |
| Dec 1991 | $473.41 M(+266.3%) | - |
| Dec 1990 | $129.24 M | - |
FAQ
- What is AstraZeneca annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for AstraZeneca?
- What is AstraZeneca annual cash & cash equivalents year-on-year change?
- What is AstraZeneca quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for AstraZeneca?
- What is AstraZeneca quarterly cash and cash equivalents year-on-year change?
What is AstraZeneca annual cash & cash equivalents?
The current annual cash & cash equivalents of AZN is $5.84 B
What is the all time high annual cash & cash equivalents for AstraZeneca?
AstraZeneca all-time high annual cash & cash equivalents is $10.70 B
What is AstraZeneca annual cash & cash equivalents year-on-year change?
Over the past year, AZN annual cash & cash equivalents has changed by -$326.00 M (-5.29%)
What is AstraZeneca quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AZN is $4.80 B
What is the all time high quarterly cash and cash equivalents for AstraZeneca?
AstraZeneca all-time high quarterly cash and cash equivalents is $15.57 B
What is AstraZeneca quarterly cash and cash equivalents year-on-year change?
Over the past year, AZN quarterly cash and cash equivalents has changed by -$74.00 M (-1.52%)